Stock ALTME TME PHARMA N.V.
Add to a list
To use this feature you must be a member
Log inSign up

TME Pharma N.V. Stock

Equities

ALTME

NL0015000YE1

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:13 2024-05-09 am EDT 		5-day change 1st Jan Change
0.245 EUR -3.54% Intraday chart for TME Pharma N.V. +0.62% +6.52%
Apr. 25 TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 23 TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 - Sales 2023 - Capitalization 1.22M 1.13M
Net income 2022 -15M -13.91M Net income 2023 -6M -5.56M EV / Sales 2022 -
Net cash position 2022 548K 508K Net cash position 2023 1.08M 1M EV / Sales 2023 -
P/E ratio 2022
-0.09 x
P/E ratio 2023
-0.17 x
Employees 13
Yield 2022 *
-
Yield 2023
-
Free-Float 9.94%
More Fundamentals * Assessed data

Chart TME Pharma N.V.

Dynamic Chart

Latest news about TME Pharma N.V.

TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer CI
TME Pharma: Fast Track designation in glioblastoma CF
TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer CI
Invest Securities Keeps TME Pharma at Buy, Trims PT MT
TME PHARMA : Invest Securities slightly adjusts its target CF
TME Pharma: green light from the FDA to launch a ph.II trial CF
TME Pharma N.V. Announces FDA Clearance of Investigational New Drug Application for Nox-A12 Phase 2 Trial in Brain Cancer CI
TME Pharma: end of convertible bond program CF
TME Pharma Raises EUR1.5 Million to Buy Back Convertible Bonds MT
TME Pharma N.V. announced that it expects to receive ?1.479999 million in funding CI
TME Pharma On Track to Complete Clinical Trial Protocol for Brain Cancer Therapy by Q1 MT
TME Pharma Announces Successful Advice Meeting with US Food and Drug Administration on Nox-A12 Development in Brain Cancer CI
TME Pharma N.V. announced that it has received ?2.7 million in funding CI
TME PHARMA : Invest Securities updates its target CF
More news

Analyst Recommendations on TME Pharma N.V.

Invest Securities Keeps TME Pharma at Buy, Trims PT MT
TME PHARMA : Invest Securities slightly adjusts its target CF
TME PHARMA : Invest Securities updates its target CF
TME PHARMA : Invest Securities confirms its recommendation CF
Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer CI
More recommendations

Press releases TME Pharma N.V.

TME Pharma Publishes 2023 Financial Results and Provides Operating Update BU
TME PHARMA ANNOUNCES 33% OF PATIENTS RECEIVING NOX-A12 IN COMBINATION WITH BEVACIZUMAB AND RADIOTHERAPY ACHIEVE TWO-YEAR SURVIVAL IN GLORIA PHASE 1/2 TRIAL IN BRAIN CANCER AQ
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer BU
TME Pharma N : Inside Information / Other news releases PU
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer BU
More press releases

News in other languages on TME Pharma N.V.

En Direct des Marchés : TotalEnergies, Saint-Gobain, Safran, Airbus, Unibail, BHP, Microsoft, Alphabet...
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS 2023 ET FAIT LE POINT SUR SES NOMBREUSES AVANCÉES OPÉRATIONNELLES
C'est parti pour les publications de résultats à la chaîne
En Direct des Marchés : Renault, SAP, Sanofi, TotalEnergies, Novartis, Legrand, Tapestry, OVH...
TME PHARMA ANNONCE QUE 33% DES PATIENTS AYANT REÇU LE NOX-A12 EN COMBINAISON AVEC LE BEVACIZUMAB ET LA RADIOTHÉRAPIE ONT ATTEINT DEUX ANS DE SURVIE DANS L'ESSAI DE PHASE 1/2 GLORIA DANS LE CANCER DU CERVEAU
More news

Quotes and Performance

1 day-3.54%
1 week+0.62%
Current month-3.92%
1 month-13.88%
3 months+3.59%
6 months-43.29%
Current year+6.52%
More quotes

Highs and lows

1 week
0.24
Extreme 0.239
0.26
1 month
0.23
Extreme 0.226
0.30
Current year
0.21
Extreme 0.205
0.44
1 year
0.19
Extreme 0.1902
2.20
3 years
0.19
Extreme 0.1902
52.00
5 years
0.19
Extreme 0.1902
123.00
10 years
0.19
Extreme 0.1902
2 200.00
More quotes

Managers and Directors - TME Pharma N.V.

Managers TitleAgeSince
Aram Andrew Mangasarian CEO
 Chief Executive Officer 54 10-04-30
Heike Balzer DFI
 Director of Finance/CFO - 99-12-31
Ewelina Staniuk IRC
 Investor Relations Contact - 17-12-31
Members of the board TitleAgeSince
Cornelis Alexander Izeboud BRD
 Director/Board Member 53 20-06-29
Maurizio PetitBon CHM
 Chairman 76 16-08-31
Susan Coles BRD
 Director/Board Member 58 21-06-23
More insiders

Quotes

Date Price Change Volume
24-05-09 0.245 -3.54% 189 047
24-05-08 0.254 -0.39% 90,645
24-05-07 0.255 +2.00% 226,127
24-05-06 0.25 +0.60% 148,433
24-05-03 0.2485 +2.05% 192,014

Real-time Euronext Paris, May 09, 2024 at 11:35 am EDT

More quotes

Company Profile

TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
Sector
Biotechnology & Medical Research
Calendar
2024-10-23 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TME PHARMA N.V. Stock TME Pharma N.V.
+6.52% 7.76M
MODERNA, INC. Stock Moderna, Inc.
+24.44% 46.71B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.8B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.94% 41.52B
CELLTRION, INC. Stock Celltrion, Inc.
-5.86% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.99% 25.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.06% 19.26B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+3.12% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.17% 12.08B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.08% 11.98B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALTME Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW